Mycophenolic Acid
181
relevant articles (10 outcomes,
18 trials/studies)
found for this Drug
Description:
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Also Known As:
Acid, Mycophenolic; -Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-
Relationship Network
Drug Context: Research Results
Experts
| 1. | van Gelder, T:
3 articles
(09/2008 - 06/2003)
|
| 2. | Weimar, W:
2 articles
(09/2008 - 06/2003)
|
| 3. | von Müller, Lutz:
2 articles
(07/2007 - 07/2006)
|
| 4. | Czock, David:
2 articles
(07/2007 - 07/2006)
|
| 5. | Rasche, Franz Maximilian:
2 articles
(07/2007 - 07/2006)
|
| 6. | Keller, Frieder:
2 articles
(07/2007 - 07/2006)
|
| 7. | Krautkramer, E:
1 article
(09/2008)
|
| 8. | Bijl, A H:
1 article
(09/2008)
|
| 9. | Lichter, P:
1 article
(09/2008)
|
| 10. | Muranyi, W:
1 article
(09/2008)
|
Related Diseases
| 1. | Psoriasis (Pustulosis Palmaris et Plantaris)
|
| 2. | Neoplasms (Cancer)
|
| 3. | Pemphigus (Pemphigus Vulgaris)
|
| 4. | Cardiovascular Diseases (Cardiovascular Disease)
08/01/2004
- " In addition, the activity profiles identified for the immunosuppressants mycophenolic acid, cyclosporin A, and FK-506 provide a potential explanation for a reduced incidence of posttransplant cardiovascular disease in patients receiving mycophenolic acid. " 03/01/2003
- " Because chronic injury to renal allografts, as well as the dominant complications of renal transplantation such as cardiovascular disease and skin cancers, are woven together by a common theme of excessive proliferative activity, albeit of different cell types, long-term therapy will be directed at both protecting the allograft and the allograft recipient by incorporating as long-term therapy selected anti-proliferative agents that could include inhibitors of the renin-angiotensin-aldosterone system, statins, sirolimus, mycophenolic acid and leflunomide."
Order ALL the reference details at left...
|
| 5. | Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II)
|
|
Related Drugs and Biologics
Related Therapies and Procedures